Evidence map›Paper›PMID 35871433›Full record

ArticleNeurochemical research2022

Loureirin C and Xanthoceraside Prevent Abnormal Behaviors Associated with Downregulation of Brain Derived Neurotrophic Factor and AKT/mTOR/CREB Signaling in the Prefrontal Cortex Induced by Chronic Corticosterone Exposure in Mice.

Yang Yang, Akihiro Mouri, Qiaohui Lu, Kazuo Kunisawa, Hisayoshi Kubota, Masaya Hasegawa, Mami Hirakawa, Yuko Mori, Zou Libo, Kuniaki Saito and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Chronic salmon calcitonin exerts an antidepressant effectFrontiers in molecular neuroscience · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Yang Yang *Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Akihiro Mouri *Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan. mouri@fujita-hu.ac.jp.ORCID http://orcid.org/0000-0003-3833-4041
Qiaohui LuDepartment of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Kazuo KunisawaDepartment of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Hisayoshi KubotaDepartment of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Masaya HasegawaDepartment of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Mami HirakawaDepartment of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Yuko MoriDepartment of Advanced Diagnostic System Development, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Zou LiboDepartment of Pharmacology, Life Science and Biopharmaceutics School, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Kuniaki SaitoDepartment of Advanced Diagnostic System Development, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Toshitaka NabeshimaAdvanced Diagnostic System Research Laboratory, Fujita Health University, Graduate School of Health Sciences, Toyoake, Aichi, 470-1192, Japan.
Fujita Health University · JPShenyang Pharmaceutical University · CN

Funding

Japan Science and Technology Agency JPMJFR215HJapan Society for the Promotion of Science 17H04252Japan Society for the Promotion of Science 20K07931Japan Society for the Promotion of Science 20K16679
6 · The paper itself

Abstract

Brain derived neurotrophic factor (BDNF) is one of the most abundant neurotrophic factors, and its deficits are involved in the pathogenesis of major depressive disorders (MDD). Loureirin C (Lou C) is a compound derived from red resin extracted from the stems of Chinese dragon's blood. Xanthoceraside (Xan) is a triterpenoid saponin extracted from the husks of Xanthoceras sorbifolia Bunge. These compounds have neuroprotective effects through upregulation of BDNF. The present study aimed to evaluate whether Lou C and Xan attenuate abnormal behaviors induced by chronic corticosterone (CORT) administration. CORT was administered subcutaneously to mice for 3 weeks, and Lou C and Xan, dispensed orally once a day during the last 2 weeks of CORT administration. Chronic CORT administration induced abnormal behaviors such as prolonged starting latency in the open field test, decreased social interaction time in the social interaction test and prolonged latency to eat in the novelty suppressed feeding test. Chronic CORT administration decreased the expression levels of BDNF and the phosphorylation of protein kinase B (Akt), mammalian target of rapamycin (mTOR), and the cAMP response element binding protein (CREB) in the prefrontal cortex. Lou C and Xan dose-dependently prevented the abnormal behaviors and decreased the expression levels of BDNF and in phosphorylation of AKT, mTOR, and CREB in the prefrontal cortex of CORT mice. These results suggest that Lou C and Xan could be attractive candidates for pharmacotherapy of MDD at least in part, given their propensity to increase BDNF expression and phosphorylation of AKT, mTOR, and CREB.

Indexed as

Major Depressive DisorderSaponinsTriterpenesAnimalsBrain-Derived Neurotrophic FactorCorticosteroneCyclic AMP Response Element-Binding ProteinDepressionDown-RegulationHippocampusMicePrefrontal CortexProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesBrain-Derived Neurotrophic FactorCorticosteroneCyclic AMP Response Element-Binding ProteinProto-Oncogene Proteins c-aktSaponinsTOR Serine-Threonine KinasesTriterpenesxanthocerasideBrain-derived neurotrophic factorCorticosteroneDepressionLoureirin CXanthoceraside

Identifiers

PMID35871433
OpenAlexW4286797670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.